#USA #Duluth #VitaSmart™ #organ preservation #Hope

Bridge to Life Reports Breakthrough Findings on HOPE

Bridge to Life™ Ltd. has recently announced significant findings at the 2026 International Liver Transplantation Society (ILTS) Congress in Geneva. These studies showcase the potential of VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) to broaden the scope of using marginal donor livers, thus addressing the growing need for transplantable organs. The efficacy of HOPE lies not only in its ability to preserve the mitochondrial function but also in its real-time assessment capabilities, making it a pioneering solution in organ preservation.

The research highlights HOPE's significance in improving outcomes for livers previously deemed unsuitable for transplantation due to criteria such as steatosis or advanced donor age. "HOPE is more than a preservation technique; it's an organ recovery mechanism that enhances clinical decision-making and ultimately saves lives," remarked Don Webber, CEO of Bridge to Life Ltd. This emphasizes how the approach helps transition from conventional organ preservation to a more nuanced process of precision transplantation.

The Science Behind HOPE's Adoption

The studies presented demonstrate that utilizing HOPE can enhance acceptance rates of donor organs significantly. One multicenter matched-cohort study conducted across several Spanish hospitals revealed that this method effectively expands donor acceptance criteria. The results indicated that organs subjected to HOPE exhibited comparable outcomes to those preserved traditionally, with striking reductions in early allograft dysfunction and ischemic cholangiopathy. Notably, the mortality rate at 90 days was diminished, illustrating the undeniable benefits of HOPE for high-risk transplants.

In another study, researchers focused on recovering discarded livers that would typically be deemed unsuitable after they encountered challenges during regional normothermic perfusion. By employing HOPE, they observed a notable increase in the utilization rates of liver grafts from controlled donation after circulatory death (cDCD) donors, advocating for re-assessing protocols for organ eligibility.

Mitochondrial Function and Logistical Flexibility

Further enhancing the excitement is the investigation into the profound implications of HOPE on mitochondrial viability. Recent inquiries conducted by the Cleveland Clinic Foundation suggested that extended HOPE, lasting up to 24 hours, maintained mitochondrial function effectively while permitting procedural flexibility. When comparing four-hour versus twelve-hour durations of HOPE, no significant differences in mitochondrial injury were noted, paving the way for longer preservation times without compromising organ quality. This breakthrough could revolutionize logistical operations in transplantation, allowing for daytime surgeries and more efficient organ allocations.

The insights gained from assessing flavin mononucleotide (FMN) as a biomarker shed light on the importance of mitochondrial health. It was found that FMN levels in donor serum correlate directly with mitochondrial integrity, potentially serving as a rapid assessment tool for organ quality before transplantation. The prospect of quantifying FMN signals promises to refine acceptance protocols, significantly improving donor utilization rates.

Conclusion

The findings from Bridge to Life at ILTS 2026 not only bolster the clinical case for HOPE in expanding liver transplantation outcomes but also underscore the vital need for innovative solutions to tackle the global organ shortage. As the healthcare community anticipates further developments, HOPE emerges as a beacon of hope for many individuals awaiting life-saving transplants, marking a pivotal shift in organ preservation technology.

In conclusion, the commitment of Bridge to Life in advancing organ preservation and transplantation technology heralds a new era of possibilities for such critical health concerns. It remains to be seen how wider adoption of HOPE will reshape the landscape of transplantation in the coming years.